Monkeypox Treatment: Scientists are trying to find out the reason behind the spread of monkeypox; Some antiviral drugs are effective, know their names

At present, the spreading infection of monkeypox around the world has become a cause of concern. In the course of ongoing research to diagnose it, it has been found that some antiviral drugs can reduce the symptoms of the disease as well as shorten its infectious period. In a paper published in the journal The Lancet Infectious Disease, the researchers detail their earlier research on seven patients who contracted monkeypox infection in the UK between 2018 and 2021.

These drugs work

Researchers have reported that two antiviral drugs - brincidofovir and tecovirimat - may be helpful in treating this disease. According to the study, there is evidence of clinical benefit of brisidofovir, while more research is needed on tecovirimat.

What is the reason for the spread, scientists engaged in understanding

The author of the research, Dr Hugh Adler, said that a team report from Liverpool University Hospital states that the mankipox virus has been found in blood and throat swabs. It is currently unclear what caused the monkeypox outbreak in Europe and North America in May 2022.

Studies on the use of antivirals

It is also worth noting that the people who have been suffering from this disease have neither travel history nor any known link in the past. Therefore, our study is the first trial of antiviral use in the treatment of monkeypox in humans.

Drug Effect

Initially three patients were given brincidofovir for seven days after infection developed rash. This showed a difference in the liver blood test. According to the researchers, it is not known what the clinical outcome of different doses of brisidofovir was, but all three patients and one patient made a complete recovery. All three cases of monkeypox were reported in the UK in 2021.

Did not have to face pneumonia

One was treated with tecoviramat and found that the symptoms of the virus in the upper respiratory tract were short-lived. The infection remained low in all the patients and no one suffered a serious condition. No one suffered pneumonia or sepsis due to monkeypox. However, one patient showed mild symptoms again after six weeks. So some more research is still needed.